Rapamycin for Longevity: Evidence, Dosing, and Risks

Rapamycin (sirolimus) is the closest thing to a proven longevity drug in laboratory science. It is the only intervention that reliably extends maximum lifespan in mammals across multiple independent studies, including in genetically heterogeneous mice, and it works even when administration begins in late middle age — a finding that generated enormous interest in the longevity research community.

The mechanism is clear: rapamycin inhibits mTORC1 (mechanistic target of rapamycin complex 1), a central nutrient-sensing hub that, when chronically active, accelerates the hallmarks of aging. By intermittently suppressing mTOR signaling, rapamycin induces autophagy, reduces cellular senescence, improves mitochondrial quality control, and mimics aspects of caloric restriction at the cellular level.

The human data is fragmentary. Rapamycin is an FDA-approved immunosuppressant used at high chronic doses in organ transplant patients, where its risks — infection susceptibility, metabolic effects, wound healing impairment — are well-characterized and accepted as trade-offs for preventing rejection. The longevity application uses far lower, intermittent doses with a fundamentally different risk-benefit calculation.

**The Animal Evidence**

The ITP (Interventions Testing Program), the gold standard for testing longevity interventions in mammals, has shown rapamycin extends median and maximum lifespan in C57BL/6 mice by 10–15% when started at equivalent "middle age" — and even when started at the equivalent of 60 human years. This is not subtle or disputed. Rapamycin is in a different evidence category than any supplement.

The caveat: mice are not humans. Every previous drug that extended lifespan in mice has failed to translate to humans in large trials. The reasons include differences in mTOR biology, immune system structure, and the fundamental difference between a 2-year lifespan and an 80-year lifespan. The animal evidence is genuinely exciting and justifies human trials; it does not justify widespread self-administration.

**The Human Evidence**

Human rapamycin longevity data is limited to:

1. **PEARL trial** — the first randomized controlled trial of low-dose rapamycin in healthy aging adults. Published 2023 (Kaeberlein et al.). Primary endpoints included biological age markers, immune function, and safety. Results showed acceptable safety at 5mg/week and 10mg/week over 48 weeks. Some participants showed improvements in immune markers. The trial was not powered to show lifespan effects. This is the most rigorous human data available.

2. **Rejuvenation Roadmap cohort** — observational data from longevity-focused physicians (principally Peter Attia, Matt Kaeberlein) using rapamycin in practice. Case series and practitioner reports suggest tolerable side effects at intermittent low doses (2–6mg/week), with the most common adverse effects being mouth sores (aphthous ulcers) and temporary lipid changes.

3. **Organ transplant safety data** — extensive safety data from chronic high-dose use (2–5mg/day) in immunosuppression. This data is not directly applicable to intermittent low-dose longevity protocols but characterizes the adverse effect profile.

**The Proposed Longevity Protocol**

Longevity-focused physicians who prescribe rapamycin off-label typically use: - 2–6mg once weekly (not daily) - Intermittent dosing to allow mTOR recovery (avoiding chronic suppression that impairs wound healing and immune function) - Regular monitoring: fasting lipids, fasting glucose, CBC, infection risk assessment - Exclusion criteria: active infections, pregnancy, immunocompromised states, certain cancers

The rationale for weekly intermittent dosing over daily dosing is that it may capture the mTOR inhibition benefit (autophagy induction, senescent cell clearance) while reducing the cumulative immunosuppression and metabolic effects of daily administration. This is pharmacologically reasonable but has not been directly compared to daily dosing in human longevity trials.

**The Risks You Must Understand**

Rapamycin is not a supplement. The risk profile at longevity doses is meaningfully different from transplant doses but non-trivial:

*Immune suppression:* Even at low weekly doses, rapamycin impairs immune surveillance. Increased susceptibility to infections, impaired vaccine responses (timing matters), and theoretical risk of reduced cancer immune surveillance are real concerns. For adults over 60 with baseline immune senescence, this trade-off deserves careful individual assessment.

*Metabolic effects:* Rapamycin causes insulin resistance and can worsen lipid profiles, particularly triglycerides, in some users. Regular monitoring is required.

*Wound healing:* mTOR is essential for tissue repair. Elective surgery should be paused 2–4 weeks before procedures.

*Aphthous ulcers:* Mouth sores are the most commonly reported side effect at longevity doses — uncomfortable but manageable.

*Drug interactions:* Rapamycin is metabolized by CYP3A4; strong inhibitors (grapefruit, ketoconazole, some macrolide antibiotics) can dramatically increase blood levels.

**Who This Is For**

Rapamycin longevity use should currently be limited to: - Adults over 50 with no active infections, autoimmune conditions, or planned surgeries - Those with physician oversight, baseline bloodwork, and monitoring protocols - Those who have fully optimized lifestyle foundations (exercise, diet, sleep) — rapamycin is not a shortcut around lifestyle - Those with realistic expectations: this is a calculated bet on animal data, not a proven human longevity intervention

Rapamycin is not appropriate for self-administration without medical supervision, online-only consultation, or as a first-line longevity intervention before lifestyle optimization.

**Context Within Everspan's Intervention Database**

Everspan grades rapamycin as Grade B− for longevity specifically — exceptional animal data, emerging and encouraging human safety data, no human lifespan endpoints yet. This places it in a unique position: mechanistically stronger than almost any supplement, but with a risk profile that requires clinical oversight that no supplement requires.

For adults motivated by the rapamycin evidence, the practical path is to find a longevity-focused physician who has experience with off-label use, understand the monitoring requirements, and approach it as a clinical protocol rather than a supplement addition.